Incidence of Acute Kidney Injury After Administration of Iodine Contrast Media in Patients With Reduced Renal Function

Launched by UPPSALA UNIVERSITY · Dec 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at whether using iodine contrast media (a special dye used in certain imaging tests) increases the risk of acute kidney injury in patients with severely reduced kidney function. The study will include patients who need a CT scan and have a kidney function score (measured by a test called eGFR) of less than 30. To participate, patients must be 65 years or older and cannot be currently receiving certain medications that could harm the kidneys or undergo kidney replacement therapy.

Participants in the study will have blood and urine samples taken before their CT scan and again at three and 21 days after the scan. The researchers want to understand how easy or difficult it is to decide whether to use the iodine contrast media and whether using it could improve patient care or be lifesaving. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research that may help improve care for patients with kidney issues in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • eGFR \<30 mL/min/1.73m2, calculated with the revised Lund-Malmö formula and plasma creatinine.
• • Medical need of either an ICM-enhanced or unenhanced CT
• Exclusion Criteria:
• • \<18 years of age
• • Ongoing renal replacement therapy
• • Ongoing treatment with nephrotoxic drugs. Drugs classified as nephrotoxic are acyclovir, aminoglycosides, ciclosporins, cisplatin, methotrexate, non-steroidal anti-inflammatory drugs (except low-dose aspirin) and vancomycin administered intravenously.
• • Known allergy to ICM who and have not received prophylactic treatment (if patient belongs to ICM arm)